ReviewFrontiers in immunology2026
The role of microbiota on thyroid cancer: from carcinogenicity, treatment and predictability.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, more and more attention has been paid to the mechanism of microbiota in thyroid cancer (TC). Gut microbiota (GM) and its metabolites can regulate the immune system and affect thyroid function through the gut-thyroid axis. When the GM is dysregulated, the intestinal barrier function is impaired, resulting in immune dysfunction, chronic inflammation, oncogene activation, and eventually leading to the occurrence of TC. In addition, intratumoral microbiota (ITM) is also directly involved in the occurrence, progression and invasion of TC. However, the mechanism of action between the microbiome and TC is still under exploration, and the research results in this field will have a major impact on disease cognition and clinical intervention. Chemotherapy, radiation, and immunotherapy are the main non-surgical treatments for TC. Furthermore, gut microbiota modulators, including probiotics and prebiotics, represent a potential therapeutic strategy for TC, offering new avenues for individualized treatment. In addition, the differences of microbiota in patients with TC can be used to predict tumor subtype, invasion, lymph node metastasis, and the efficacy of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.